Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects
Status:
Completed
Trial end date:
2019-07-08
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-centre, open-label, parallel-group study in subjects with moderate
hepatic impairment and subjects with normal hepatic function. Child-Pugh (CP) scoring will be
used to determine hepatic impairment.